Advancing to Berkeley: BloodScan Selected for the 2026 Taiwan–Berkeley Health Innovation Accelerator (SPH)
BloodScan Selected for the 2026 Taiwan–Berkeley Health Innovation Accelerator, Strengthening Global Commercialization Strategy
BloodScan is honored to announce its official selection for the 2026 Taiwan–Berkeley Health Innovation Accelerator. This highly competitive international acceleration platform, jointly initiated by Taiwan and the UC Berkeley School of Public Health, is dedicated to supporting high-potential medical and biotech startups, accelerating the clinical translation of innovative technologies, and fostering global commercialization.
This selection not only represents international recognition of BloodScan's technological development direction and market strategy but further validates the innovative value of our work in the field of Circulating Tumor Cell (CTC) isolation and liquid biopsy technology.
BloodScan’s core technology, Labyrinth One, is a proprietary microfluidic platform capable of high-efficiency, label-free isolation of circulating tumor cells (CTCs) while maintaining cell viability to support subsequent molecular analysis and functional research, with applications in translational medicine and precision oncology.
This milestone further solidifies BloodScan's market position in the field of next-generation liquid biopsy technology and reinforces the company's long-term vision of driving innovation in early cancer detection and precision medicine.